NGF is a growth factor for which the role in the promotion of angiogenesis is still not completely understood. We found that NGF promotes the pathological neovascularization process in glioma through a direct interaction with a9b1 integrin, which is up-regulated on microvascular endothelial cells in cancer tissue. We propagated gHMVEC primary cells using a new method of immune-selection, and these cells demonstrated a9b1 integrin-dependent binding of NGF in a cell adhesion assay. Moreover, NGF induced gHMVEC proliferation and chemotaxis inhibited by specific blockers of a9b1 integrin, such as MLD-disintegrins and monoclonal antibody Y9A2. A Matrigel tube formation assay revealed that NGF significantly increased capillary-like growth from gHMVEC to a level comparable to treatment with VEGF. The snake venom disintegrin, VLO5, inhibited the agonistic effect of both growth factors, whereas the effect of Y9A2 was not statistically significant. Angiogenesis exogenously induced by NGF was also a9b1-integrin dependent in an embryonic quail CAM system. However, angiogenesis pathologically induced by developing glioma in this system was only sensitive for inhibition with MLD-disintegrin, suggesting a more complex effect of cancer cells on the neovascularization process. The anti-angiogenic effect of MLD-disintegrins is probably related to their proapoptotic ability induced in activated tumoral endothelial cells. Therefore, the molecular basis of these disintegrins may be useful for developing new angiostatic pharmaceuticals for application in cancer therapy.
I
ntegrins are the major cell surface receptors, which play a structural role in proper tissue conformation. However, this apparently static activity of integrins is strengthened by their participation in cell migration in many physiological processes. Angiogenesis is an example of this type of process, and integrins expressed on the endothelial cells are very important in the promotion of cell movement in the surrounding extracellular matrix.
1,2 Currently, 10 integrin heterodimers, namely a1b1, a2b1, a3b1, a4b1, a5b1, a6b1, a6b4, a9b1, avb3, and avb5, have been characterized as mediators of angiogenesis. Angiogenesis is a neovascularization process, occurring from pre-existing vasculature. Since the time when J. Folkman observed a pathological increase in vascularization of solid tumors, 3 the mechanisms regulating this process have been intensively studied. Many laboratories are focused on designing effective inhibitors of pathological vessel growth, and integrins are a potential key target in these investigations. Recently, a few anti-integrin compounds were introduced into clinical trials involving patients with cancer as angiostatic therapeutics. However, these studies were limited to integrins reacting with ligands containing an RGD motif. av Integrins and a5b1 integrin were targeted by therapeutic monoclonal antibodies 4, 5 or RGD-cyclic peptides. 6 Inhibition of collagen receptors, a1b1 and a2b1 integrins, showed a potent anti-tumoral effect in animal models that was directly related to inhibition of angiogenesis. 7, 8 On the other hand, 2 structurally similar integrins, a4b1 and a9b1, appeared to also be important in angiogenesis. 9, 10 Expression of these integrins was confirmed on developing endothelium, and their antagonist inhibited the pathological pro-angiogenic effect of tumor progression in vitro and in vivo.
Another very important element involved in angiogenesis initiation and progression is related to the interaction of growth factors with their receptors expressed on endothelial cells. Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) were characterized as major stimulators of endothelial cells to promote pro-angiogenic activities, such as cell proliferation and migration. VEGF has been intensively investigated to develop anti-cancer treatment resulting in the development of a therapeutical anti-VEGF monoclonal antibody (Bevacizumab). 11 Correlation between growth factor-stimulated angiogenesis and integrin involvement in this process was described as a cross-talk between receptors. 12, 13 The involvement of VEGFR2 has been shown to stimulate b3 integrin-dependent activities of endothelial cells.
14 The trans-activation of both types of receptors occurs through regulation of cytoplasmic cell signaling molecules, such as c-Src. 15, 16 A different situation occurs for a9b1 integrin. VEGF was recognized as a ligand for a9b1 integrin, which may act as an agonist for this receptor for promotion of angiogenesis. 17 Direct binding to a9b1 integrin was also demonstrated for nerve growth factor (NGF). 18 On the other hand, NGF belongs to the pro-angiogenic growth factors family, 19, 20 and its interaction with a9b1 integrin appears to be important in this process. In the present studies, we verified this hypothesis in angiogenesis assays in vitro and in vivo.
NGF specifically interacts with TrkA, which belongs to the receptor tyrosine kinase family. 21, 22 However, a distinguishable and specific feature, which differentiates it from other growth factors, is its binding to p75 NTR , a receptor that belongs to the tumor necrosis factor family. This is a common receptor that also binds other neurotrophins, such as BDNF, NT-3, and NT-4. 23 -25 TrkA and p75 NTR appear to work together as a high-affinity complex, resulting in the induction of pro-survival and pro-proliferative cell signaling. 26 -28 The unique activity characteristic for NGF is that, as a growth factor, it may stimulate cells to undergo apoptosis. This situation was observed when p75 NTR was expressed in the absence of TrkA. Mechanistic studies of this phenomenon revealed that p75 NTR induces Rac GTPase-dependent activation of c-junN-terminal kinase (JNK), including an injury-specific JNK3. 29 Recent investigation established a9b1 integrin as a third receptor for NGF, which mimics TrkA in activity. 30 
Materials and Methods

Snake Venom Disintegrins and Antibodies
Snake venom MLD-disintegrins VLO5 and bitisgabonin-2 were purified from venoms of Vipera letbetina obtusa and Bitis gabonica, respectively. RGD-containing homodimeric disintegrin VLO4 was purified also from Vipera letbetina obtusa. Two steps of reverse-phase HPLC were applied to obtain pure proteins. 31, 32 Snake venom vascular endothelial growth factor (vpVEGF) was purified from Vipera palestina as described previously. 33 b-NGF (mNGF 2.5S) was isolated from mouse submaxillary glands and kindly provided by Alomone Labs. Polyclonal serum against a9 subunit of integrin cytoplasmic domain was developed commercially in rabbit (Millipore). Monoclonal anti-human antibodies anti-a2 (clone P1E6), anti-a3 (clone C3II.1), anti-a5 (clone SAM-1), anti-a9b1 (clone Y9A2), anti-avb3 (clone LM609), anti-b2 (clone MEM 48), anti-CD31 (clone P2B1), anti-p75 NTR (clone ME20.4), anti-CD105 (clone P3D1), and anti-factor VIII (clone 24-2-C7) were purchased from Millipore, whereas anti-a4 (HP2/1) and anti-a6 (clone GoH3) were purchased from Beckman Coulter. Anti-b-actin polyclonal antibody was purchased from Cell Signaling Technologies. Anti-a1 integrin subunit monoclonal antibody (mab) clone AQC2 was a gift from Dr. L. Fritz from Life Sciences Venture Partner. Anti-TrkA polyclonal serum was kindly provided by Dr. Louis Reichardt.
Cells Propagation and Culturing
Glioma human microvascular endothelial cells (gHMVEC) were isolated from tumor tissue obtained from patients undergoing standard surgical procedure for diagnosed glioblastoma multiform (GBM). Tissue (0.5 -1 g) was placed in ice-cold Hank's balanced salt solution (HBSS) supplemented with penicillin/streptomycin and 250 mg/mL amphoterycin B for transportation. Isolation procedure was performed within 1 hour after GBM dissection. Tissue was cut on small pieces ( 10 mm 3 ) and digested with collagenease II (Worthington Biochemical) by incubation at 378C for 1 h. Digested tissue was squeezed through metal mesh, washed by centrifugation with HBSS, and placed in tissue culture flasks in the presence of complete endothelial cell basal media-2 (EBM-2; Lonza Walkerscille). Cells were allowed to grow and proliferate for 1 week and then trypsynized.
For separation of gHMVEC from cancer cells, we used immunoadhesion sorting. Anti-CD31 mab (5 mg/ mL) was immobilized on a 6-well plate in PBS by overnight incubation at 48C. Plate was blocked with 1% BSA in HBSS for 1 h at room temperature. Trypsynized cells were washed and applied on the well at a concentration of 1 × 10 6 per mL in HBSS containing 1% BSA. Immunoadhesion was conducted by 30 min. Wells were intensively washed 5 times with HBSS containing 1% BSA and, finally, by EBM-2. Unattached cancer cells were cultured for another purposes. Firmly attached gHMVEC were detached using a scraper and transferred to a plate for culturing.
LBC3 cell line was developed from GBM tissue after surgical resection from a 56-year-old female patient. All procedures for propagation of cells were the same as described for gHMVEC. Primary glioma cells were collected as nonattached to the anti-CD31 mab in immunoadhesion selection protocol. They spontaneously immortalized after several passages and were cultured using DMEM containing 10% FBS.
Primary cardiac HMVEC (cHMVEC) were purchased from Lonza and cultured using the same media as gHMVEC. LN229 cell line was purchased from ATCC and cultured using the same media as for LBC3 cell line.
Immunohistochemistry
Immunohistochemistry was performed in formalinfixed, paraffin-embedded tissue sectioned at a 5-mm thickness. The tissue microarray slide of normal brain and different stages of astrocytic tumors was purchased from US Biomax. Moreover, GBM cases were supplemented with our own collection obtained from the Neurosurgery Department. Immunohistochemistry was performed as was published previously. 34 In brief, formalin-fixed, paraffin-embedded tissue was deparaffinized in xylene and dehydrated through descending solutions of ethanol to water, and non-enzymatic antigen retrieval in 0.01 M sodium citrate buffer (pH, 6.0) heated to 958C for 40 min in a vacuum oven was performed. After cooling, the slides were rinsed in PBS and incubated in methanol/3% H 2 O 2 for 20 min to quench endogenous peroxidase. After blocking with 5% normal horse or goat serum, the slides were incubated with primary antibody overnight at room temperature in a humidified chamber. Biotinylated secondary antibody was added and incubated for 1 h at room temperature. For a colorimetric reaction, the slides were incubated with avidin-biotin complexes (ABC kit, Vector Laboratory) for 1 hour at room temperature and developed with diaminobenzidine (Roche). Finally, the sections were counterstained with hematoxylin and mounted with Permount. For fluorescence reactions, the slides were incubated with FITC-streptavidin (green) or Texas Red-streptavidin (red) secondary antibodies and mounted with an aqueous-based mounting media. Images were analyzed using an Olympus AX70 light microscope with fluorescence filters and with magnifications of 400×.
Cell Adhesion Assay
Cell adhesion was performed using CMFDA (5-chloromethylfluororescein diacetate) -labeled cell tracker, as described previously. 35 RNA silencing of a9 integrin subunit was performed in serum-free media by transfection with siRNA (0.1 mM; Ambion) using Lipofectamine in Opi-MEM media. After 72 h of transfection, cells were detached, labeled with CMFDA, and investigated in adhesion assay for interaction with growth factors. Effectiveness of a9 integrin subunit gene silencing was tested in Western blot and cell adhesion assay to immobilized Y9A2 mab (Supplementary material, Fig. S1 ).
Cell Proliferation Assays
Cell viability was performed using 6-well plate for the cells growing. gHMVEC were grown to 60% -70% of confluence and starved for 24 h. Media containing 2% FBS or NGF were added in the presence or absence of bitisgabonin-2. Cells were trypsynized and counted every 24 h for a total 72 h. First counting was performed after 24 h of treatment. Dead cells were distinguished by staining with trypan blue and not counted.
Cell proliferation assay was performed using BrdUrd kit (Roche), as described previously. 10 
Cell Migration Assay (Chemotaxis)
Cell migration assay was performed in Boyden's chamber using 8 mm pore size membrane inserts (HTS FluoroBlok inserts; BD Biosciences), according to procedure described previously. 10 
Wound Healing In Vitro Assay
Wound healing assay was performed using CytoSelect kit (Cell Biolabs). Cells were seeded on 24-well plate containing inserts for artificial wound creation (0.9 mm). The next day, inserts were removed, wells were washed with serum-free media, and cells were treated or not with NGF (200 ng/mL) containing or not inhibitors of a9b1 integrin. For positive control, cells were treated with 2% FBS. Progression of wound closing was monitored by taking phase-contrast pictures at a magnification of 100× at times 0 and 24 h. Images were analyzed using ImageJ software. The percentage of wound closure was calculated after 24 h and normalized to the wound area at time 0.
Matrigel Tube Formation Assay (Angiogenesis In Vitro)
Growth factor-reduced Matrigel was plated onto 24-well plates and incubated at 378C for 30 min. gHMVEC were seeded at 5 × 10 4 /well in EBM-2 containing or not NGF or vpVEGF and the appropriate a9b1 integrin inhibitor. After 24 h, the medium was removed, and the cells washed twice with PBS and fixed with 4% paraformaldehyde. Images were analyzed using an Olympus microscope with 100× magnification. Numbers of tubes per observation field were estimated and averaged for each well. All wells were coded and monitored by investigators who were blinded for this protocol to avoid any significant imprecision of tube-like structure density determination.
Glioma Growth and Angiogenesis Induction in CAM Quail Embryonic Model
The quail embryonic model angiogenesis was developed on the basis of a previously published assay. 36 Fertilized Japanese quail (Coturnix coturnix japonica) eggs were purchased from Boyd's Bird. Eggs were cleaned with ethanol and maintained at 378C until embryonic day 3 in incubator without CO 2 . The shells were then opened with a razor blade and sterile scissors, and the contents transferred into 6-well tissue culture plates and returned to the 378C incubator. At embryonic day 7, NGF in the absence or presence of a9b1 integrin inhibitors was applied directly on the membrane in 0.5 mL of total volume of PBS used as a vehicle. Embryos were returned to the 378C and, after 24 h, fixed by 5 mL of prewarmed 2% gluteraldehyde, 4% paraformaldehyde in PBS for 48 h at room temperature. The membrane was dissected and mounted onto glass slides for evaluation of fractal dimension (D f ) as described elsewhere. 36 The tumor growth and induction of pathological angiogenesis in the embryonic quail system was previously developed in our laboratory. 8, 30 In brief, experiment until day 7 was designed identically as described above. At embryonic day 7, LBC3 cells (1 × 10 7 / 50 mL) were applied on the top of CAM and allowed to grow for 24 h. Embryos were divided into experimental groups, each containing at least 10 animals, and VLO5 (20 mg per treatment) or Y9A2 (5 mg per treatment) were applied in 50 mL of PBS on the top of a tumor every day (5 treatments). The control group received a vehicle (PBS) treatment. The experiment was performed until day 13. After fixation (as above), membranes containing tumor were dissected and mounted onto the glass slide for evaluation of fractal dimension. The area of CAM selected as a square for analysis of vascularization ratio was localized in the opposite site to the tumor on the membrane (Fig. 7B ). For example, if tumor was developed in the right corner of the CAM, the vascularization tree for analysis was framed in the left corner of membrane.
Statistical Analysis
Statistical analysis was performed using 1-way ANOVA with all pairwise multiple comparison procedures (Holm-Sidak method) for overall significance level at .05. Calculation was performed using SigmaStat (SPSS).
Results
Expression of a9b1 Integrin on Normal Brain and Glioma Endothelium
Varieties of integrins present on the endothelial cells are strongly up-regulated during malignant transformation, suggesting their significance in the pathological development of neo-vasculature. The increase of expression of a9b1 integrin on vascular endothelium was correlated with progressing grades of glial tumors, as was shown by IHC studies (Fig. 1A) . Normal brain exhibited very low levels of endothelial cells positively labeled with anti-a9, whereas low-grade astrocytoma and anaplastic astrocytoma demonstrated a significant progressive elevation of this integrin. The endothelial cells present in the GBM vasculature were the most abundant in expression of a9b1 integrin. Double labeling of normal brain and GBM tissues confirmed association a9b1 integrin with endothelial cells and its over-expression in the cancer tissue (Fig. 1B) . A specific antibody against factor VIII was used as an endothelial cell marker in this experiment. Malignant transformation of astrocytes was also correlated with expression of a9b1 integrin, as we reported previously. 30 
Expression of a9b1 Integrin on gHMVEC
Endothelial cells were isolated from GBM tissue using an immunoadhesion selection method. The most important step of this procedure included sorting of cells according to their adhesion to immobilized monoclonal antibody against the endothelial cell surface protein CD31. This very quick and effective method efficiently separated gHMVEC from the tumoral cells after culturing of proliferating cells in passage 0. Expression of a9b1 integrin was sensitive for the length of culturing and disappeared from the cellular surface in passages .5. Therefore, all presented experiments were performed in passages 2-4. In these passages, gHMVEC expressed a9b1 integrin, as was confirmed by 3 different assays using as a positive control antibodies against 3 endothelial cell markers (Fig. 2) . The immunocytostaining experiments showed strong labeling of cells with antibody against a9 integrin subunit that was observed under a fluorescence microscope. Antibody against factor VIII was used as a positive marker of endothelial cells (Fig. 2A) . Flow cytometry analysis confirmed the presence of a9b1 integrin on the cells positive also for CD31 (Fig. 2B) . The lysate of gHMVEC was analyzed in Western blot using anti-a9 polyclonal antibody and showed the presence of this integrin (Fig. 2C) . Monoclonal antibody against CD105 (endoglin) was applied to detect a positive marker for endothelial cells. The lysate of cHMVEC was used as a negative control of cells that do not express a9b1 integrin, whereas LN229 cells were used as a positive control. Finally, a9b1 integrin was identified on the gHMVEC using cell immunoadhesion array. The expression of a majority of b1 integrin family members was detected on glioma endothelial cells in this assay. Presence of a9b1 integrin was found in all gHMVEC, which were propagated from 3 different clinical cases of GBM (Fig. 2D ). These cells were negative for a4b1 integrin and in b2 integrin subunit that was used as a control IgG. The gHMVEC also express avb3 integrin to a high level. All cells showed similar levels of a9b1 integrin expression when used in the early passages.
Involvement of a9b1 Integrin in the NGF-induced Pro-angiogenic Activities of gHMVEC Direct interaction of NGF with gHMVEC was investigated in a cell adhesion assay. Cells adhered to immobilized NGF in the dose-dependent fashion, whereas the same concentrations of bFGF used in the experiment were not effective to induce adhesion of gHMVEC (Fig. 3A) . Adhesion of gHMVEC to NGF was significantly reduced for the cells with silenced a9 integrin subunit. Snake venom MLD-containing disintegrins were also tested as inhibitors of NGF interaction with a9b1 integrin expressed on gHMVEC in this assay. VLO5 and bitisgabonin-2 were effective to block adhesion of gHMVEC to NGF (Fig. 3B) . The level of inhibition was higher in the case of VLO5, although bitisgabonin-2 was also effective in a similar range. Of interest, both disintegrins were efficient to block adhesion of gHMVEC to immobilized NGF at picomolar concentrations. Inhibitory effect of RGD-containing dimerc disintegrin VLO4 was not observed for blocking adhesion of gHMVEC to NGF. Anti-a9b1 mab inhibited adhesion of gHMVEC to immobilized NGF, whereas blocking mabs against collagen receptors (a1b1 and a2b1 integrins), fibronectin receptor (a5b1 integrin), or vitronectin receptor (avb3) were not active in this assay (Supplementary material, Fig. S2) .
One of these disintegrins, bitisgabonin-2, was tested in gHMVEC proliferation and cell migration assays. NGF stimulated gHMVEC proliferation to an extent similar as FBS that was measured by cell viability and BrdU assays (Fig. 4) . Bitisgabonin-2 potently blocked NGF-stimulated cell proliferation by reducing timedependent cell number (Fig 4A) and decreasing incorporation of an analog of thymidyne in a BrdU assay (Fig. 4B) to the level of nonstimulated cells. The direct effect of MLD-disintegrins on NGF-dependent stimulation of cell growth suggests that the interaction of this growth factor with a9b1 integrin is crucial for the pathological process of proliferation of microvascular endothelial cells in cancer angiogenesis.
A cell migration experiment also revealed importance of a9b1 integrin interaction with NGF in this process. One of the major steps of new vessel formation is migration of endothelial cells in the surrounding matrix. NGF showed the ability to induce this activity of gHMVEC in Boyden's chamber chemotaxis experiments (Fig. 5A) . The saturation point of cell migration was observed after 3 h and remained constant up to 18 h. Similar time responses took place for 2% FBS, although the level of induction of chemotaxis was significantly higher than for NGF. The NGF-dependent chemotaxis was completely blocked by specific inhibitors of a9b1 integrin, such as MLD-disintegrin and Y9A2 mab. Interaction of a9b1 integrin with NGF during gHMVEC migration was confirmed in the scratch wound healing assay (Fig. 5B, Supplementary material, Fig. S3 ). The artificial wound closure was induced by NGF to the level similar to positive control (2% FBS). MLD-disintegrins and Y9A2 mab significantly inhibited NGF-induced migration of gHMVEC in this assay.
Matrigel tube formation is considered as an angiogenesis assay in vitro. We tested the ability of NGF to induce formation of tube-like structure in growth factor-reduced Matrigel, in comparison with VEGF. We used VEGF isolated from snake venom (vpVEGF), which previously showed pro-angiogenic activity. 33 NGF was similar to the vpVEGF in stimulation of the development of capillary-like structures of gHMVEC, although the number of tubes was significantly lower (Fig. 6) . Antagonists of a9b1 integrins completely abolished NGF-dependent tube formation. Y9A2 was active only in the case of NGF, whereas in vpVEGF assay, no significant effect of this mab was observed. On the other hand, VLO5 and bitisgabonin-2 inhibited capillary-like structure formation induced by both growth factors, suggesting indirect effect on VEGF stimulation. This effect may include induction of apoptosis after binding of MLD-disintegrin to a9b1 integrin on the cell surface. 30 
Effect of Interaction of NGF with a9b1 Integrin on Angiogenesis In Vivo
Investigation of the pro-angiogenic activity of NGF was performed in a CAM quail embryonic assay. Treatment of developing embryos with NGF resulted in significant increase of membrane vascularization (Fig. 7A) . This effect was abolished by inhibitors of a9b1 integrin. Both MLD-disintegrins and Y9A2 mab decreased the level of angiogenesis to the range of vehicle treated (PBS) control embryos. All 3 components were not active to block physiological angiogenesis of quail embryos, because their treatment in the absence of NGF shows no effect on vasculature ratio (data not shown).
Interaction of a9b1 integrin with NGF appears to be also important in pathological angiogenesis, induced by experimentally developed GBM on the CAM. In this assay, tumor was formed after implantation of LBC3 cells and affected the vascularization of the entire embryonic membrane. The glioma-induced development of vasculature was observed under a microscope. The increase of glioma-induced vessel density in the CAM was quantified by evaluation of the angiogenesis index as a fractal dimension (D f ) in the area on membrane placed in the opposite site (Fig. 7B) . Treatment of the tumor by VLO5 significantly inhibited pathological angiogenesis on the membrane. The effect of this snake venom disintegrin was related to its interaction with embryonic vasculature, because LBC3 cells do not express Fig. 3 . Interaction of gHMVEC with NGF in cell adhesion assay. (A) Adhesion of gHMVEC or gHMVEC with silenced by siRNA a9 integrin subunit to immobilized NGF and bFGF. Growth factors at different concentrations were immobilized on 96-well plate by overnight incubation in PBS at 48C. CMFDA-labeled cells suspended in HBSS containing calcium and magnesium were added to cells previously blocked with BSA and incubated by 30 min at 378C. Non-adhered cells were washed out and adhered cells were lysed by 0.5% Triton X-100. Fluorescence units were measured using a fluorescence microplate reader, with the bottom reading option, at an excitation wavelength of 485 nm using a 530 nm emission filter. (B) Inhibition of adhesion of gHMVEC to immobilized NGF (10 mg/mL) by snake venom disintegrins. MLD-disintegrins VLO5 and bitisgabonin-2 or RGD-disintegrin, VLO4 were preincubated with CMFDA-labeled gHMVEC prior to addition to the wells with immobilized NGF. The error bars represent the standard deviation from three independent experiments performed with gHMVEC from three different clinical cases of GBM. a9b1 integrin. Of interest, effect of anti-a9b1 integrin mab was not significant for inhibition of tumor-induced angiogenesis, suggesting the involvement of other pro-angiogenic factors secreted by tumoral cells.
Discussion
The studies of the role of integrins in the progression of glioma may answer many questions related to the mechanisms of aggressive and difficult to treat brain tumors. In the present study, we focused on angiogenesis in the context of the interaction of a9b1 integrin with NGF. Expression of a9b1 integrin on endothelial cells in vivo in different organs of human body was reported previously. 10 However, in the present studies, we showed that this integrin is significantly overexpressed on glial tumor endothelium. The increase of its expression was correlated with increased grade of malignancy. A similar association was observed for cancer cells and, in GBM, was the most abundant in this integrin. On the other hand, the presence of a9b1 integrin on normal astrocytes was negligible. 30 Therefore, in certain cases, a9b1 integrin appears to be an indicator of brain tumor malignancy and a good pharmacological target.
Investigation of a9b1 integrin on microvascular endothelial cells is difficult, because it disappears from the cell surface during their detachment from the tissue matrix and propagation in tissue culture. Its expression on microvascular endothelium was detected by immunohistochemistry on lung, brain, and heart. However, it was not observed on the surface of primary endothelial cells isolated from these organs. 10 The exemption was only the skin. Primary dHMVEC were suitable to perform a series of experiments to show the involvement of a9b1 integrin on the pro-angiogenic activities of microvascular endothelial cells. 10 The lack of stability of expression of a9b1 integrin on cell surface was not only characteristic for endothelial cells. The LBC3 glioma cell line developed by us is a9b1 integrin negative, whereas immunohistochemical analysis of the tissue of its origin showed a positive staining of cancer cells with anti-a9 integrin subunit antibody. The stimulatory effect of NGF on angiogenesis was observed previously, although the mechanism of its action is not fully understood. The pro-proliferative activity of NGF was found for primary endothelial cells propagated from normal human 37 or rat tissue 38 and for brain microcapillary endothelial cell clone bEND3. 39 Normal endothelial cells express TrkA, which in association with p75 NTR , activates a MAPKErk1/2 cell signaling pathway. 40, 41 a9b1 integrin also activates this pathway in response to NGF binding. 18 gHMVEC were negative for TrkA, whereas they express p75 NTR , as was determined by Western blot (data not shown). The pro-proliferative and NGF-dependent activity of gHMVEC appeared to be associated with a9b1 integrin, because MLD-disintegrin inhibited this process. Moreover, gHMVEC showed a potent pro-adhesive property to immobilized NGF, which was also a9b1 integrindependent. Of interest, NGF used as a chemoattractant strongly stimulated gHMVEC to migrate in Boyden chamber, and this stimulation was inhibited by a9b1 integrin blockers. Antagonists of a9b1 integrin were also effective in significant reduction of NGF-induced artificial wound closure. On the other hand, NGF induced TrkA-dependent migration of normal endothelial cells to a very low level, although statistically significantly. 42 This observation suggests that over-expression of integrin increases invasiveness and activation of endothelial cells during pathological vessel growth in malignant tissue.
TrkA and p75 NTR are not pro-adhesive but characterized as cell signaling receptors, and cells expressing them do not adhere to NGF. 18, 30 Our previously published studies revealed that TrkA and a9b1 integrin may work as complementary receptors. 30 TrkA is down-regulated according to the level of malignancy in the case of glioma cancer cells, whereas a9b1 integrin is up-regulated. A similar situation may occur for endothelial cells. Normal rat brain capillary endothelial cells were TrkA positive, 38 whereas those isolated from glioma human tissue were negative for this tyrosine kinase type receptor. Of interest, expression of TrkA and its phosphorylated form was detected on endothelial cells in clinical tissues from patients with ovarian carcinoma. 43, 44 The differential level of expression of particular NGF receptors on tumoral endothelial cells in different organs may be related to autocrine secretion of various regulatory molecules, which stimulate angiogenesis on one hand and regulate their respective receptor levels on another hand.
The up-regulation of NGF has been found in a variety of cancer tissues, including brain tumors. There are also many reports showing production of VEGF by cancer and endothelial cells following NGF stimulation. 19, 45 This indirect angiogenic effect of NGF appears to be nonrelated to a9b1 integrin. Our capillary-like formation assay showed that blocking of a9b1 integrin by monoclonal antibody completely abolished the pro-angiogenic effect of NGF, whereas the effect of VEGF was unchanged. Of interest, VEGF is also a ligand for a9b1 integrin and participation of this ligand/receptor interaction was confirmed for the neovascularization process. 17, 46 The inactivity of Y9A2 mab in this assay may be related to high level of expression of VEGFR on endothelial cells propagated from glioma tissue, which is not sensitive for inhibition of a9b1 integrin. In this context, behavior of a9b1 integrin appears to be different than avb3 integrin, which was recognized as a regulator of angiogenesis and an interesting therapeutic agent. This integrin was also characterized as a direct receptor for other pro-angiogenic growth factor, FGF. 47 However, in vitro interaction of avb3 with FGF required activation by 1 mM Mn
2+
. Several cross-talk activities were described for avb3 and VEGFR2, which was correlated with angiogenic response for both cell surface receptors. 48 Moreover, Y9A2 demonstrated a very low and statistically insignificant inhibitory effect on glioma-induced angiogenesis in quail CAM assay (Fig. 7B) , confirming that a9b1 integrin is rather not implicated in cross-talk pathways with other modulators of pathological angiogenesis induced by cancer cells including growth factor receptors. In this in vivo assay, we used glioma LBC3 cells line, which does not express a9b1 integrin, to avoid any direct blocking of tumor cell growth by integrin inhibitors, which may affect secretion of stimulatory molecules inducing pathological angiogenesis in the entire CAM. MLD-disintegrin, VLO5 inhibited experimental tumor growth in that assay when LN229 cells were implanted to the membrane. This cell line endogenously expresses a9b1 integrin. 30 MLD-disintegrins were found to inhibit angiogenesis in all presented experiments, even in those in which mab against a9b1 integrin was not effective. Explanation of this phenomenon may comprise the ability of disintegrins to induce apoptosis in targeted cells. Our experiments with LN229 cells revealed a caspase-dependent pro-apoptotic effect of VLO5. 30 A similar situation appears to be accurate for gHMVEC. Of interest, MLD-disintegrins induced an intrinsic, mitochondrialdependent apoptotic pathway, in contrast to avb3 integrin, which was involved in caspase 8 activation. 49 Therefore, a9b1 and avb3 integrins may promote angiogenesis using different mechanisms. Additional studies of the interaction of MLD-disintegrins with cancer-derived endothelial cells may lead to development of new anti-angiogenic pharmaceuticals, which may be alternatives to RGD-peptides currently tested in clinical trials of glioma.
Supplementary Material
Supplementary material is available at Neuro-Oncology Journal online (http://neuro-oncology.oxfordjournals.org/).
